EN / CN

News

Current Position: Home ››  News

Levamlodipine Besylate API Approved for Marketing!

Release Date:2026-06-23 17:02:10    Views:3193

      Newland Pharmaceutical's Levamlodipine Besylate API has been approved for marketing by China's National Medical Products Administration (NMPA), marking an important step in the company's expansion into cardiovascular APIs. The approval also offers formulation manufacturers a more reliable and cost-effective supply option.

List of Approved API Products

      With continuous R&D investment and efficient registration & submission work, our company has established an API portfolio covering multiple therapeutic areas including anti-infectives, cardiovascular & cerebrovascular drugs, anesthetics & analgesics, gastrointestinal medicines, anti-allergy agents and iron supplements. The key products and their applications are listed below:

微信图片_20260920115121_912_27.png

Pipeline Updates

      Ruxolitinib Phosphate, Ilaprazole, and other products are progressing as planned. We will continue to expand our portfolio of specialty APIs and develop new products to create greater value for our customers.